THURSDAY, Sept. 12, 2024 -- For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free...

FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with...

TUESDAY, Sept. 17, 2024 -- The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with...

Interstitial Cystitis Clinical Trials Interstitial Cystitis companies are Seikagaku Corporation, UCB, Alivio Therapeutics, Merck, Teva Pharmaceutical,...

Interstitial Lung Disease Clinical Trials Interstitial Lung Disease companies are AstraZeneca, CSL Behring, Syndax Pharmaceuticals, Taiho...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated...

Artificial intelligence revolutionizes gene mutation prediction in lung cancer, offering more accurate, faster insights for personalized treatment...

Levodopa-induced Dyskinesia Market DelveInsight’s analysts project market growth, fueled by increasing prevalence, improved diagnostics,...

Levodopa-induced Dyskinesia Market DelveInsight’s analysts project market growth, fueled by increasing prevalence, improved diagnostics,...

TUESDAY, Sept. 17, 2024 -- A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney...